CEACAM5 and cancer: This approach has the benefit of generating CEA peptide-specific CD8+ T cell responses but has the limitation that we can only vaccinate a portion of cancer patients that express a particular HLA phenotype and that CEA-specific CD4+ T cell responses may not be activated.